Opioids for non-operable osteoarthritis and soft-tissue rheumatism

Arthritis Research and Therapy

Volumn 7, Issue 5, 2005, Pages 193-194

  Dickson, David John ^a,b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b Langbaurgh Primary Care Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GLUCOSAMINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; RUBEFACIENT;

ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CONSTIPATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NAUSEA; NONARTICULAR RHEUMATISM; OPIATE ADDICTION; OSTEOARTHRITIS; PAIN ASSESSMENT; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY OF LIFE; RESPIRATORY FAILURE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEDATION; SIDE EFFECT; SOMNOLENCE; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; EUROPE; GASTROINTESTINAL DISEASES; HUMANS; MIDDLE AGED; NARCOTICS; OPIOID-RELATED DISORDERS; OSTEOARTHRITIS; PAIN; PRACTICE GUIDELINES; RHEUMATIC DISEASES; SLEEP DISORDERS, INTRINSIC; XEROSTOMIA;

EID: 25144503423     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1817     Document Type: Article

References (10)

1. Moore A, McQuay HJ: Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arth Res Ther 2005, 7:R1046-R1051
2. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma J-WJ, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, et al.: EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for the International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
3. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Jordan K, Kaklamanis P, et al.: EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64: 669-681.
4. American Pain Society: APS & ACR guidelines. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. Glenview, IL: American Pain Society; 2002.
5. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000, 43:1905-1915.
6. Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG: Around-the-Clock, Controlled-Release Oxycodone Therapy for Osteoarthritis-Related Pain: Placebo-Controlled Trial and Long-term Evaluation. Arch Intern Med 2000, 160:853-860.
7. Schug SA, Zech D, Grond S: Adverse effects of systemic opioid analgesics. Drug Saf 1992, 7:200-213.
8. Definitions Related to the Use of Opioids for the Treatment of Pain: A Consensus Document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine, 2001 [http://www.ampainsoc.org/advocacy/opioids2.htm]
9. The American Society of Addiction Medicine. Public policy statement on Definitions related to the use of opioids in pain treatment, 1997. [http://www.asam.org/pain/definitions2.pdf]
10. European Medicines Agency [www.emea.eu.int]